| 0.6199 0.101 (19.37%) | 05-22 15:28 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.88 | 1-year : | 1.02 |
| Resists | First : | 0.75 | Second : | 0.88 |
| Pivot price | 0.43 |
|||
| Supports | First : | 0.45 | Second : | 0.26 |
| MAs | MA(5) : | 0.54 |
MA(20) : | 0.42  |
| MA(100) : | 0.35 |
MA(250) : | 1.88 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 81.2 |
D(3) : | 81 |
| RSI | RSI(14): 64.4 |
|||
| 52-week | High : | 4.46 | Low : | 0.23 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RLMD ] has closed above the upper band by 4.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 75.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.66 - 0.66 | 0.66 - 0.67 |
| Low: | 0.48 - 0.49 | 0.49 - 0.49 |
| Close: | 0.51 - 0.52 | 0.52 - 0.52 |
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Tue, 13 May 2025
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript - Insider Monkey
Tue, 13 May 2025
Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ... - Yahoo Finance
Tue, 13 May 2025
Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights - GuruFocus
Tue, 13 May 2025
Relmada Therapeutics Reports Q1 2025 Financial Results - TipRanks
Thu, 08 May 2025
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - TradingView
Thu, 08 May 2025
Relmada Therapeutics, Inc. Announces Conference Call to Discuss Q1 2025 Financial Results and Business Progress - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 17 (%) |
| Held by Institutions | 39.7 (%) |
| Shares Short | 2,030 (K) |
| Shares Short P.Month | 1,620 (K) |
| EPS | -2.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -73.2 % |
| Return on Equity (ttm) | -132.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -0.24 |
| PEG Ratio | 0 |
| Price to Book value | 0.52 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|